Sword Health Raises US$85m in Series C

 In News, Start-Up, Venture Capital

Sword Health, the Portuguese virtual musculoskeletal care provider, has announced an US$85M Series C funding round. This news follows SWORD’s US$25 million Series B in January, bringing the company’s total to $135M in funding to-date. The newest Series C round was led by General Catalyst with participation from BOND, Highmark Ventures, and BPEA, along with returning investors Khosla Ventures, Founders Fund, Transformation Capital, and Green Innovations.

MSK disorders are one of the leading causes of chronic pain and disability, affecting over 2Bn people worldwide. The current healthcare system has answered this crisis with expensive and often unnecessary surgical procedures, failing to relieve MSK pain and often putting patients at risk of dependency on both prescription and over-the-counter pain medications. Funds from SWORD Health’s round will be used to build the leading value-based MSK platform that leverages SWORD Health’s best-of-breed virtual physical therapy program to drive significant cost savings to payers, employers and providers.
“SWORD has been the foremost pioneer in the virtual MSK care space,” said CEO and founder of SWORD Health, Virgílio Bento. “We were the first company to introduce sensor-based technology to treat patients alongside a Doctor of Physical Therapy, and the first to deploy a global solution that treats patients across 3 continents. Now it’s time to pioneer this space again by developing the leading results-oriented, value-based virtual musculoskeletal care provider model in the world and decrease the cost of high-quality MSK treatment for all.”
SWORD Health provides care for MSK conditions, and puts preventative measures in place for high risk individuals by working directly with payers, employers and providers. The digital solution is the most comprehensive on the market, covering acute, chronic, and preventative care, with striking results for back, shoulder, neck, knee, elbow, hip, ankle and wrist areas. The holistic solution improves individuals’ overall health and wellbeing while offering industry-leading outcomes for businesses by lowering absenteeism and lifetime healthcare costs for individuals.
Clients are seeing in SWORD a clearly differentiated solution, addressing a critical and expensive health care challenge. According to Amy Broghammmer, Health and Welfare Benefits Manager at Danaher, “Associates with MSK conditions account for 51% of Danaher’s medical spend when factoring other comorbidities. To make sure we were solving the right problem we did significant research, interviews, and an RFP to find the best MSK solution. That research and our experience with SWORD’s solution confirmed that their clinical-grade offering is the most comprehensive, engaging, and effective solution on the market. The results they achieved in our associates are a testament to this. After 12 weeks, we saw an 80% decrease in surgery intent, a 49% pain reduction and a 72% increase in productivity. Working with their team has been an amazing experience and the impact we have both seen and heard from our members speaks for itself.”
In addition to raising US$110M in just 6 months, the company has grown its brand through the acquisition of numerous new clients and increased user base on the platform. SWORD Health has recently increased their number of patients being treated over 1000% YoY, which in turn has seen a 600% growth for their overall revenue YoY.
“Treatment of musculoskeletal disorders costs the US health system alone in excess of US$300B per year. SWORD Health has set the new standard of therapy in MSK by combining novel hardware, software and physician-directed care. Their digital-led model brings high quality treatment right into members’ homes to create a more personalised, engaging and effective experience,” said Chris Bischoff, Managing Director, General Catalyst. “We’re impressed by the performance of SWORD Health and are excited to partner with Virgilio and the team to further improve patient outcomes and reduce unnecessary costs in MSK for payers, employers and providers — helping solve one of the most important and urgent problems in healthcare.”